<DOC>
	<DOCNO>NCT02842866</DOCNO>
	<brief_summary>The aim study demonstrate non-inferiority immunogenicity evaluate safety single dose MenACYW conjugate vaccine compare single dose Menomune® - A/C/Y/W-135 adult 56 year age old US . Primary objective : - To demonstrate non-inferiority vaccine seroresponse meningococcal serogroups A , C , Y , W follow administration single dose MenACYW conjugate vaccine compare observe follow administration single dose Menomune® - A/C/Y/W-135 . Secondary objective : - To compare hSBA antibody geometric mean titer ( GMTs ) meningococcal serogroups A , C , Y , W follow administration MenACYW conjugate vaccine observe following administration Menomune® - A/C/Y/W-135 Observational objective : - To describe antibody titer meningococcal serogroups A , C , Y , W measure hSBA baseline ( vaccination ) 30 day vaccination MenACYW conjugate vaccine Menomune® - A/C/Y/W-135 . - To describe safety profile MenACYW conjugate vaccine compare license Menomune® - A/C/Y/W-135 single administration .</brief_summary>
	<brief_title>Immunogenicity Safety Investigational Quadrivalent Meningococcal Conjugate Vaccine Adults 56 Years Older</brief_title>
	<detailed_description>Subjects randomize 1:1 ratio receive single dose MenACYW conjugate vaccine Menomune® - A/C/Y/W-135 Day 0 ( Visit 1 ) . They undergo immunogenicity assessment baseline ( pre-vaccination ) 30 44 day post-vaccination also evaluate safety Day 180 post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥ 56 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination ) Participation 4 week precede trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week ( 28 day ) precede trial vaccination plan receipt vaccine prior Visit 2 except influenza vaccination , may receive least 2 week study vaccine . This exception include monovalent pandemic influenza vaccine multivalent influenza vaccine Previous vaccination meningococcal disease either trial vaccine another vaccine ( i.e. , mono polyvalent , polysaccharide , conjugate meningococcal vaccine contain serogroups A , C , Y , W ; meningococcal B vaccine ) Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal infection , confirm either clinically , serologically , microbiologically At high risk meningococcal infection trial ( specifically , limit , subject persistent complement deficiency , anatomic functional asplenia , subject travel country high endemic epidemic disease ) Known systemic hypersensitivity latex vaccine component , history lifethreatening reaction vaccine use trial vaccine containing substance Personal history GuillainBarré syndrome Personal history Arthuslike reaction vaccination tetanus toxoidcontaining vaccine within least 10 year propose study vaccination Verbal report thrombocytopenia , contraindicate intramuscular vaccination , Investigator 's opinion Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Investigator 's opinion Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 100.4°F ) . A prospective subject include study condition resolve febrile event subside Receipt oral injectable antibiotic therapy within 72 hour prior first blood draw Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>MenACYW conjugate vaccine</keyword>
	<keyword>Menomune® - A/C/Y/W-135</keyword>
</DOC>